Anticytokine therapies in systemic lupus erythematosus

Immunotherapy

Volumn 2, Issue 4, 2010, Pages 575-582

  La Cava, Antonio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anticytokine therapy; clinical trial; cytokine; immunotherapy; systemic lupus erythematosus

Indexed keywords

A 623; ALPHA INTERFERON; AMG 811; ATACICEPT; AZATHIOPRINE; B CELL ACTIVATING FACTOR; B N10; BELIMUMAB; BR3 FC; BRIOBACEPT; CYTOKINE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RONTALIZUMAB; SIFALIMUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; HUMAN; IMMUNE RESPONSE; INFECTION COMPLICATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DIFFERENTIATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CYTOKINES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 77955008714     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.29     Document Type: Review

References (61)

1. Mok CC: Update on emerging drug therapies for systemic lupus erythematosus. Expert Opin. Emerg. Drugs 15(1), 53-70 (2010).
2. Jacob C, McDevitt H: Tumour necrosis factor-α in murine autoimmune lupus nephritis. Nature 331(6154), 356-358 (1988).
3. Brennan D, Yui M, Wuthrich R, Kelley V: Tumor necrosis factor α nd IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J. Immunol. 143(11), 3470-3475 (1989).
4. Edwards C, Zhou T, Zhang J et al.: Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-α . J. Immunol. 157(4), 1758-1772 (1996).
5. Yokoyama H, Kreft B, Kelley V: Biphasic increase in circulating and renal TNF-α in MRL-lpr mice with differing regulatory mechanisms. Kidney Int. 47(1), 122-130 (1995).
6. Aringer M, Smolen J: SLE - complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res. Ther. 5(4), 172-177 (2003).
7. Gabay C, Cakir N, Moral F et al.: Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J. Rheumatol. 24(2), 303-308 (1997).
8. Lacki J, Leszczynski P, Kelemen J, Mller W, Mackiewicz S: Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. J. Med. 28(1-2), 99-107 (1997).
9. Studnicka-Benke A, Steiner G, Petera P, Smolen J: Tumour necrosis factor α and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br. J. Rheumatol. 35(11), 1067-1074 (1996).
10. Charles P, Smeenk R, De Jong J, Feldmann M, Maini R: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43(11), 2383-2890 (2000).
11. De Rycke L, Kruithof E, Van Damme N et al.: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 48(4), 1015-1023 (2003).
12. Shakoor N, Michalska M, Harris C, Block J: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359(9306), 579-580 (2002). (Pubitemid 34178442)
13. Carlson E, Rothfield N: Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 48(4), 1165-1166 (2003).
14. Stokes M, Foster K, Markowitz G et al.: Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol. Dial. Transplant. 20(7), 1400-1406 (2005).
15. Aringer M, Steiner G, Graninger W et al.: Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 56(1), 274-279 (2007).
16. Hayat S, Uppal S: Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus. Mod. Rheumatol. 17(2), 174-177 (2007). (Pubitemid 46614367)
17. Aringer M, Graninger WB, Steiner G, Smolen J: Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open label study. Arthritis Rheum. 50(10), 3161-3169 (2004).
18. Feng X, Wu H, Grossman J et al.: Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54(9), 2951-2962 (2006).
19. Baechler E, Batliwalla F, Karypis G et al.: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100(5), 2610-2615 (2003).
20. Bengtsson A, Sturfelt G, Truedsson L et al.: Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9(9), 664-671 (2000).
21. Balomenos D, Rumold R, Theofilopoulos A: Interferon-g is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101(2), 364-371 (1998).
22. Jacob C, van der Meide P, McDevitt H: In vivo treatment of (NZB NZW)F1 lupus-like nephritis with monoclonal antibody to g interferon. J. Exp. Med. 166(3), 798-803 (1987).
23. Lawson B, Prudhomme G, Chang Y et al.: Treatment of murine lupus with cDNA encoding IFN-γR/Fc. J. Clin. Invest. 106(2), 207-215 (2000).
24. Nicoletti F, Di Marco R, Zaccone P et al.: Dichotomic effects of IFN-g on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. Eur. J. Immunol. 30(2), 438-447 (2000).
25. Uhm W, Na K, Song G et al.: Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 42(8), 935-938 (2003).
26. Min D, Cho M, Cho C et al.: Decreased production of interleukin-12 and interferon-g is associated with renal involvement in systemic lupus erythematosus. Scand. J. Rheumatol. 30(3), 159-163 (2001).
27. Horai R, Saijo S, Tanioka H et al.: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191(2), 313-320 (2000).
28. Kiberd B, Stadnyk A: Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule? Immunopharmacology 30(2), 131-137 (1995).
29. Takemura T, Yoshioka K, Murakami K et al.: Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch. 424 (5), 459-464 (1994).
30. Sturfelt G, Roux-Lombard P, Wollheim F, Dayer J: Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br. J. Rheumatol. 36(12), 1283-1289 (1997).
31. Suzuki H, Takemura H, Kashiwagi H: Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity. Arthritis Rheum. 38(8), 1055-1059 (1995).
32. Ostendorf B, Iking-Konert C, Kurz K et al.: Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis. 64(4), 630-633 (2005).
33. Kiberd B: Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J. Am. Soc. Nephrol. 4(1), 58-61 (1993).
34. Finck BK, Chan B, Wofsy D: Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest. 94(2), 585-591 (1994).
35. Stuart R, Littlewood A, Maddison P, Hall N: Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin. Exp. Rheumatol. 13(1), 17-22 (1995).
36. Horii Y, Iwano M, Hirata E et al.: Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int. 39, S71-75 (1993).
37. Yoshio T, Masuyama J, Kohda N et al.: Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J. Rheumatol. 24(3), 489-495 (1997).
38. Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D: Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus 1(2), 111-117 (1992).
39. Illei GG, Shirota Y, Yarboro CH et al.: Tocilizumab in systemic lupus erythematosus. data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label Phase I dosage-escaltion study. Arthritis Rheum. 62(2), 542-552 (2010).
40. Ishida H, Muchamuel T, Sakaguchi S et al.: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179(1), 305-310 (1994).
41. Yin Z, Bahtiyar G, Zhang N et al.: IL-10 regulates murine lupus. J. Immunol. 169(4), 2148-2155 (2002).
42. Houssiau F, Lefebvre C, Vanden Berghe M et al.: Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4(5), 393-395 (1995).
43. Llorente L, Zou W, Levy Y et al.: Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 181(3), 839-844 (1995).
44. Llorente L, Richaud-Patin Y, Couderc J et al.: Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum. 40(8), 1429-1435 (1997).
45. Llorente L, Richaud-Patin Y, Garca-Padilla C et al.: Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43(8), 1790 - 1800 (2000).
46. Litinskiy M, Nardelli B, Hilbert D et al.: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3(9), 822-829 (2002).
47. Scapini P, Nardelli B, Nadali G et al.: G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J. Exp. Med. 197(3), 297-302 (2003).
48. Gross J, Dillon S, Mudri S et al.: TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 15(2), 289-302 (2001).
49. Stohl W, Metyas S, Tan S et al.: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48(12), 3475-3486 (2003).
50. Stohl W: SLE - systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res. Ther. 5(3), 136-138 (2003).
51. Ng L, Sutherland A, Newton R et al.: B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. 173(2), 807-817 (2004).
52. Cancro MP, DCruz DP, Khamashtam MA: The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J. Clin. Invest. 119(5), 1066-1073 (2009).
53. Seshasayee D, Valdez P, Yan M et al.: Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18(2), 279-288 (2003).
54. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator. Drugs RD 9(3), 197-202 (2008).
55. von Blow G, van Deursen J, Bram R: Regulation of the T-independent humoral response by TACI. Immunity 14(5), 573-582 (2001).
56. Lee C, Hymowitz S, Wallweber H et al.: Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood 108(9), 3103-3111 (2006).
57. Lin W, Gong Q, Seshasayee D et al.: Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood 110(12), 3959-3967 (2007).
58. Stohl W, Merrill JT, Looney RJ et al.: Phase 1a single- and Phase 1b multiple-dose studies of AMG 623 (an anti-BAFF peptibody) in systemic lupus erythematosus (SLE). Arthritis Rheum. 58(9), S565-S566 (2008).
59. Fleischmann R, Wei N, Shaw M et al.: BR3-Fc Phase I study: safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects of a novel BR3-Fc fusion protein in patients with rheumatoid arthritis. Arthritis Rheum. 54(9), S229-S230 (2006).
60. Ratner M: Human Genome Sciences trial data wow lupus community. Nat. Biotechnol. 27(9), 779-780 (2009).
61. BENLYSTA® (belimumab) www.hgsi.com/belimumab.htm